Your Article Summary
See Latest ArticlesAustrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/18/06
Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal the ruling, but the patent will remain in effect during the appeals process. Lipitor is sold in Austria under the brand name Sortis
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA drug approval intervals from 1997 to 2006: analysis and comparison during information technology implementation
International Journal of Electronic Healthcare , 12/01/09
Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan
GlaxoSmithKline, 12/01/09
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease
Shire, 11/30/09